US equities |
NVDA $181.60 ▼-9.26% MU $656.39 ▼-17.46% AMD $404.40 ▼-17.26% TSLA $343.69 ▼-10.77% AAPL $344.17 ▼-1.53% SNDK $806.43 ▼-22.26% MSFT $535.93 ▼-3.58% AMZN $260.21 ▼-2.19%
FinancialContent

Bio-Rad Laboratories, Inc. Class A Common Stock (NY:BIO)

369.00 -10.99 (-2.89%)
Official Closing Price Updated: 7:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Bio-Rad Laboratories, Inc. Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports Second-Quarter 2026 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Participate in Upcoming Investor Conferences
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports First-Quarter 2026 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports Third-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad's Management to Participate in Upcoming Investor Conferences
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Host Droplet Digital PCR Webinar on Tuesday, August 26, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports Second-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Second Quarter 2025 Financial Results on Thursday, July 31, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Expands Droplet Digital PCR Offering Through Strategic Acquisition and Platform Rollout
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports First-Quarter 2025 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
Aggregate analysis of eight clinical trials of patients with advanced non-small cell lung cancer (aNSCLC) was supported by Biodesix, using Bio-Rad Droplet Digital™ PCR technology 
From Biodesix, Inc.
Via GlobeNewswire
News headline image
Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
From Bio-Rad Laboratories, Inc.
Via Business Wire
News headline image
Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
From Geneoscopy, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >